Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT001 dose-ranging study versus placebo and Spiriva Respimat in persistent asthma
2020-000532-22Phase 2
- Sponsor
- Pearl Therapeutics
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrrolate metered dose inhaler and tiotropium in persistent asthma (5 arms), sponsored by Pearl Therapeutics. Primary endpoint: Change from baseline in forced expiratory volume in 1 second area under the curve from 0 to 4 hours at Week 24.
02
Drugs
glycopyrrolate metered dose inhalertiotropium
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2020-000532-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000532-22.